Vial cracking causes halt in lupus drug trial

Cracked vials have led to the suspension of a clinical trial. Biotech drug developer Anthera found the cracks in vials of its experimental lupus drug, A-623, which is in Phase IIb testing.

The company announced Tuesday that it has suspended dosing and enrollment in the trial while it investigates.

Faulty vials were discovered by a clinical investigator at one of the trial sites. Upon investigation, the company found additional cracked vials in the drug storeroom of another facility. CEO Paul Truex says in a release that he's committed to resolving the issue and discussing plans with the FDA.

- see the Anthera release

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.

Roche's global manufacturing leader Pierre-Alain Ruffieux will take the reins and oversee the Moderna COVID-19 vaccine collaboration.